Gender differences in atrial fibrillation progression
Atrial fibrillation (AF) does not follow an identical course in women and men. Differences in atrial structure, electrophysiology, comorbidity patterns, hormonal exposure, symptom perception, and access to care can influence how the arrhythmia begins, recurs, and progresses from paroxysmal to persistent disease. These factors also affect stroke risk, treatment selection, procedural outcomes, and long-term quality of life.
Sex and gender are related but distinct concepts in arrhythmia research. Biological sex may shape myocardial remodeling, vascular risk, and pharmacological response, while gender-related factors can influence health-seeking behavior, referral patterns, caregiving demands, and participation in clinical studies. A clinically useful approach must consider both without treating either category as biologically uniform.
Understanding these differences is particularly important as rhythm control strategies become more individualized. Earlier detection, improved imaging, wearable monitoring, catheter ablation, and newer energy sources are changing the management pathway. Yet evidence gaps remain, especially for women with multimorbidity, older patients, and populations historically underrepresented in electrophysiology research.
Biological pathways shaping atrial remodeling
Women with AF are often diagnosed at an older age than men, although age at diagnosis varies by cohort and healthcare setting. Female patients may have a higher burden of hypertension, valvular disease, heart failure with preserved ejection fraction, and thyroid disorders when AF is identified. These conditions can increase atrial pressure, fibrosis, inflammation, and electrical heterogeneity, creating a substrate for recurrent arrhythmia.
Hormonal biology may contribute to this pattern. Estrogen affects vascular function, autonomic signaling, calcium handling, and myocardial remodeling, but its influence is complex and changes across the life course. Menopause, surgical ovarian suppression, and hormone therapy may alter cardiovascular risk profiles, although clinical data do not support simplistic assumptions about hormone exposure and AF prevention. Age-related changes in both sexes can be more important than sex alone.
Atrial size and left ventricular geometry also differ across populations. Women may develop clinically significant AF without the same degree of atrial enlargement observed in men, while diastolic dysfunction and elevated filling pressures can be prominent. In men, obesity, sleep-disordered breathing, coronary disease, and alcohol exposure are frequently important contributors. These are population-level tendencies rather than rules for individual patients, and they should not replace direct assessment of cardiac structure and risk factors.
Presentation and detection across sexes
Women with AF commonly report palpitations, fatigue, exertional intolerance, dizziness, anxiety, and reduced functional capacity. Symptoms may be more intense or may have a greater effect on daily life, even when arrhythmia burden is similar. Men may be more likely to present with incidentally detected AF or with fewer reported symptoms, which can delay recognition of intermittent episodes in either group.
The route to diagnosis matters. Paroxysmal AF can remain undetected when symptoms are brief, attributed to stress, or absent during a clinic visit. Extended ambulatory monitoring, consumer wearables, and opportunistic pulse or electrocardiographic screening may identify episodes earlier, but access and interpretation differ between healthcare systems. Clinicians should avoid assuming that a lack of palpitations indicates low arrhythmia burden.
Women have historically been referred less often for electrophysiology procedures, even when symptom burden and potential benefit are substantial. Referral delays may reflect older evidence, concerns about procedural complications, atypical symptom descriptions, or a perception that AF is primarily a male disease. Shared decision-making should therefore address symptoms, rhythm burden, atrial substrate, age, comorbidities, and patient goals rather than rely on demographic expectations.
How progression patterns differ clinically
Progression from paroxysmal to persistent AF is driven by cumulative atrial remodeling. Hypertension, obesity, diabetes, sleep apnea, inflammation, kidney disease, alcohol use, and uncontrolled ventricular rate can accelerate this transition. The relative contribution of each factor may differ by sex, but the central clinical principle is consistent: modifiable substrate should be treated alongside the rhythm itself.
Women may experience greater symptom severity and a higher risk of stroke or systemic embolism after AF is established. This does not mean that female sex should be used in isolation to determine anticoagulation. Contemporary risk assessment generally treats sex as a risk modifier within a validated score, with age, prior stroke, heart failure, hypertension, diabetes, and vascular disease carrying major weight.
Men often have earlier onset associated with cardiometabolic and lifestyle-related risk factors, while women may present later with more advanced comorbidity and diastolic disease. These patterns can influence progression, but substantial overlap exists. The comparison below summarizes commonly observed trends while emphasizing that individual evaluation remains essential.
| Clinical domain | Women with AF | Men with AF | Practical implication |
|---|---|---|---|
| Typical presentation | More symptoms, fatigue, and impaired quality of life | More incidental or less symptomatic detection in some cohorts | Measure symptom burden directly rather than infer it from rhythm documentation |
| Common associated conditions | Hypertension, valvular disease, HFpEF, thyroid disease | Coronary disease, obesity, sleep apnea, alcohol-related risk | Search actively for sex-patterned comorbidities without stereotyping |
| Thromboembolic concern | Often higher observed stroke risk after accounting for other factors | Risk remains strongly linked to age and comorbidities | Use validated risk assessment and reassess over time |
| Referral and intervention | Historically lower referral for ablation | More frequent procedural referral in many health systems | Review access, referral, and shared decision-making for equity |
| Procedural considerations | Smaller cardiac structures and vascular anatomy may affect technique | Comorbidity and substrate may influence recurrence | Individualize imaging, access planning, and follow-up |
| Quality-of-life impact | Frequently greater reported symptom and functional burden | Variable, with underreporting possible | Include patient-reported outcomes in treatment decisions |
Treatment response and procedural decisions
Rate control, rhythm control, anticoagulation, and risk-factor modification should be selected according to clinical status rather than sex alone. Women may be more susceptible to adverse drug effects because of differences in body size, renal clearance, repolarization, and baseline QT interval. Antiarrhythmic prescribing therefore requires attention to dose, kidney function, drug interactions, electrolyte abnormalities, and torsades de pointes risk.
Catheter ablation can reduce AF burden and improve symptoms in both women and men. Women are often referred later and may have more persistent AF, older age, or greater atrial remodeling at the time of intervention, factors that can lower apparent procedural success. Some studies also report higher rates of vascular complications in women, partly related to smaller vessel caliber and comorbidity. Careful vascular access, imaging when appropriate, and experienced procedural teams can help mitigate risk.
Technological development may expand the options available to patients with symptomatic AF. Early clinical experience with pulsed-field ablation illustrates interest in nonthermal energy that may reduce collateral tissue injury while achieving pulmonary vein isolation. Sex-specific comparative evidence for newer technologies remains limited, so claims of improved outcomes should be interpreted through trials that report enrollment, lesion durability, complications, and quality-of-life results by sex.
Risk assessment and longitudinal follow-up
AF management should be viewed as a longitudinal process rather than a single decision about anticoagulation or ablation. Risk profiles change as patients age or develop hypertension, heart failure, diabetes, vascular disease, or kidney dysfunction. Reassessment is especially important for women whose initial presentation may occur during a period of rapid comorbidity accumulation, and for men whose apparently low-risk profile changes over time.
Follow-up should combine rhythm surveillance with evaluation of blood pressure, weight, sleep apnea, alcohol intake, glycemic status, renal function, and exercise capacity. Patient-reported outcomes can reveal clinically important improvement or deterioration that is not captured by a brief electrocardiogram. Remote monitoring may be useful after ablation, during antiarrhythmic treatment, or when symptoms and recorded AF burden do not match.
Research communication also has a role in improving care. The Journal of Arrhythmia provides a setting for peer-reviewed work on electrophysiology, devices, ablation, guidelines, and clinical education. Broad representation in studies and transparent reporting by sex can help clinicians distinguish genuine biological differences from disparities caused by referral, treatment access, or study design.
Practical priorities for individualized care
Clinicians can translate the current evidence into a more consistent approach by combining biological insight with careful attention to structural inequities and patient preferences.
- Document sex-related risk factors and gender-related barriers separately when they affect diagnosis, treatment, or follow-up.
- Assess symptom burden, functional limitation, and quality of life even when AF episodes are brief or asymptomatic.
- Reassess stroke and bleeding risk periodically as age, comorbidities, renal function, and treatment change.
- Refer symptomatic or recurrent patients for rhythm-control discussion without allowing age or sex stereotypes to determine eligibility.
- Report enrollment, procedural outcomes, adverse events, and patient-reported results by sex in clinical research.
Building a stronger evidence base
Future studies should move beyond simple comparisons of women and men. Investigators need to examine interactions among sex, age, ethnicity, hormonal status, pregnancy history, socioeconomic conditions, and healthcare access. Standardized definitions of AF progression and consistent reporting of arrhythmia burden would make results easier to compare across cohorts.
Clinical trials of antiarrhythmic drugs, ablation technologies, implantable devices, and digital monitoring should be designed to recruit representative populations. They should also report procedural complications, repeat interventions, anticoagulation decisions, and quality-of-life outcomes separately by sex. Such reporting can identify when a treatment performs differently and when unequal outcomes arise from delayed diagnosis or unequal access.
For practicing electrophysiologists, the immediate priority is a balanced assessment: recognize patterns associated with sex and gender, then verify them against the patient’s anatomy, comorbidities, rhythm burden, and goals. Continued reading of clinical research and guideline updates can support more equitable decisions across the full course of AF care. Explore current arrhythmia research and educational resources through the journal’s open-access publications.